No Data
Zhejiang Garden Biopharmaceutical (300401.SZ): Plans to establish a subsidiary in Macau to engage in the research, production, and sales of health-related products.
On December 31, Gelonghui reported that Zhejiang Garden Biopharmaceutical (300401.SZ) announced plans to establish a subsidiary in Macau to expand its domestic and international markets and enhance the company's brand influence and market competitiveness. The establishment of a subsidiary in Macau aims to leverage Macau's international platform, expand both domestic and overseas markets, and enhance the company's brand influence and market competitiveness. Additionally, Macau has a solid industrial foundation and favorable policy environment for the research and development, production, and sales of big health products, which is beneficial for the company's big health business development.
Potential Upside For Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) Not Without Risk
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 4.8% Last Week
Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical has obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.
On November 22, Glonghui reported that zhejiang garden biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary zhejiang garden pharmaceutical co., ltd. (hereinafter referred to as "garden pharmaceutical") recently received the "pharmaceutical registration certificate" for alendronate sodium tablets approved by the National Medical Products Administration. Alendronate sodium tablets are primarily used to treat osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. Alendronate sodium tablets are classified as Category B drugs in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Directory (2023)."
Zhejiang Garden Biopharmaceutical (300401.SZ): The company's convertible bonds vitamin A project has started production.
Zhejiang garden biopharmaceutical (300401.SZ) stated on the investor interaction platform on November 11 that the company's convertible bonds vitamins A project has started production.
Huafu Securities: BASF delays the resumption time of vitamins E and A production, prices are expected to continue to rise.
Due to the explosion, BASF delayed the reproduction time of vitamins E and A. After this news was announced, vitamins E and A quickly stopped falling and rebounded.
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Shares May Have Run Too Fast Too Soon
